SAN FRANCISCO – Four large pharmas may dominate the checkpoint immunotherapy space today, but opportunities remain for companies of all sizes to improve response rates alongside checkpoint inhibitors in combinations, and to offer value through personalized approaches, execs said during an oncology panel at the BIO Investor Forum in San Francisco.
Today, the family of programmed death (PD-1/L1) checkpoint inhibitors dominates cancer immunotherapy development. Merck & Co. Inc.’s Keytruda (pembrolizumab) and Bristol-Myers Squibb Co.’s Opdivo (nivolumab) have been at...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?